DLG Naturals sold shea butter, seed oils, and Kigelia extract as unapproved new drugs (not FDA-approved) with disease-treatment claims on its website.
What happened
FDA inspected the Janesville, Wisconsin manufacturing facility on September 23, September 28, and October 6, 2021, and reviewed www.dlgnaturals.com in March 2022. FDA found the website took orders for shea butter, Kalahari melon seed oil, baobab oil, and Kigelia Africana fruit extract with claims that they treat or affect disease or body structure/function, making them unapproved new drugs. FDA also said the firm provided a Certificate of Analysis (COA), a test report, when no testing had been performed—one COA stated a mold count below a redacted limit while the lot result was 720 colony-forming units per gram—and documented cosmetic products in unlabeled containers or with incorrect lot numbers.
What FDA found
FDA found website claims that the products are intended to treat conditions such as eczema, psoriasis, burns, acne, leg ulcers, fungal infections, and boils, or to affect body function.
FD&C Act section 201(g)(1) [21 U.S.C. 321(g)(1)]Because the products are not generally recognized as safe and effective for those uses, FDA calls them new drugs.
FD&C Act section 201(p) [21 U.S.C. 321(p)]FDA says the products are unapproved new drugs and no approved applications are in effect.
FD&C Act sections 505(a) and 301(d) [21 U.S.C. 355(a) and 331(d)]FDA said the firm provided a Certificate of Analysis when no testing had been performed, and one COA stated a mold count below the redacted limit while the lot result was 720 CFU/g.
FDA documented cosmetic products stored in containers that were unlabeled or had incorrect lot numbers.
What FDA wants
FDA asks DLG Naturals to write to the office within 15 working days with the steps taken or planned to correct the violations and prevent recurrence, including documentation; if corrections cannot be completed in that time, the firm must state why and give a completion timeframe. If the firm believes the products are not in violation, it must include its reasoning and supporting information.
Who should pay attention
- cosmetic and personal-care brands buying botanical ingredients
- companies that issue or rely on Certificates of Analysis
- quality teams reviewing website claims and lot labeling
This is a summary. Read the original letter on fda.gov.